Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium
Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…Abstract Number: 191 • 2020 Pediatric Rheumatology Symposium
Utilization of Telemedicine in Pediatric Rheumatologic Care
Background/Purpose: Telemedicine has the potential for improving access to care, particularly for pediatric patients with complex needs in remote or rural locations. Previous studies have…Abstract Number: 302 • 2019 ACR/ARP Annual Meeting
Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center
Background/Purpose: Routine use of musculoskeletal ultrasound (MSK-US) to aid in clinical decision-making for rheumatology patients is less common in the United States than in Europe,…Abstract Number: 654 • 2019 ACR/ARP Annual Meeting
Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease
Background/Purpose: Undifferentiated Connective Tissue Disease (UCTD) describes the clinical scenario where a patient demonstrates characteristics of a connective tissue disease but does not meet criteria…Abstract Number: 1530 • 2019 ACR/ARP Annual Meeting
Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life. Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.…Abstract Number: 2461 • 2019 ACR/ARP Annual Meeting
Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement
Background/Purpose: Oligoarticular disease in patients with psoriatic arthritis (PsA) is often underdiagnosed and undertreated. The goal of this study is to understand and identify current…Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…Abstract Number: 2720 • 2019 ACR/ARP Annual Meeting
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…Abstract Number: 2796 • 2019 ACR/ARP Annual Meeting
The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort
Background/Purpose: Omega-3 supplementation is one of a few complementary and alternative medicine (CAM) therapies that has shown promise in improving RA symptoms through small, randomized…Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
- 1
- 2
- 3
- …
- 8
- Next Page »